Net profit down 60% deduction non-net profit increased by nearly 40% Temple of Heaven biological transformation pain period?

Recently, Tiantan Bio disclosed its third-quarter results for 2018, and announced that in the first three quarters of this year, Tiantan Bio achieved operating income of RMB2,057 million, up 27.68 percent YoY, while net profit attributable to shareholders of listed companies was RMB397 million, down 60.39 percent YoY.
embarrassing performance of Tiantan Bio also showed signs in the company's half-yearly results this year. Data show that in the first half of this year, Tiantan Bio achieved a net profit attributable to shareholders of listed companies of 240 million yuan, a decrease of 72.73 percent year-on-year.
fact, the decline in performance of the Temple of Heaven creatures this year may be understood as the "pain" of transformation. According to the announcement disclosed by Tiantan Bio, in the first three quarters of 2017, Tiantan Bio transferred its 100% stake in Beijing Beisheng Research Biological Products Co., Ltd. and 51% stake in Changchun Jian Biological Products Co., Ltd., achieving an investment income (after tax) of 758 million yuan, mainly affected by this, the company's operating profit, total profit, net profit attributable to shareholders of listed companies, basic earnings per share decreased significantly in the first three quarters of 2018.
said of the transformation, Tiantan Bio in answer to a call from securities daily reporter said: "Simply put, before Tiantan Bio's shareholders have both vaccine business and blood products business, Tiantan Bio itself has both business." The sale of the vaccine business and the purchase of their blood products business is equivalent to the consolidation of assets within the group. For
, it may not be a "hero" on the single data theory of net profit attributable to shareholders of listed companies. On the one hand, the performance gap between Tiantan Bio and the transfer of assets is shrinking from a 70% year-on-year decline in the current three-quarter report to 60% today. On the other hand, although Tiantan Bio's net profit attributable to shareholders of listed companies has not grown much, the company achieved significant growth in non-profit margins in the first three quarters of this year.
the first three quarters of this year, Tiantan Bio achieved a net profit attributable to shareholders of listed companies of 394 million yuan, up 37.96 percent year-on-year, according to the company's data. Tiantan biological aspect to the Securities Daily reporter specifically said that for the company, "professional development is certainly more advantageous, if there are vaccine business companies in the first three quarters of this year, non-net profit growth will not be so fast." The person admitted that, in fact, the company's vaccine business was a loss, the company's non-net profit growth is all brought about by the blood products business.
Previously, Tiantan Bio's first three quarters 2018 earnings report showed that the company's blood products business achieved operating income of RMB2,057 million, up 51.29% YoY;
believes that in the blood products industry is still in the background of adjustment, the company's rapid growth in performance is relatively rare, the growth momentum mainly from last year's integration of the three major optimization. According to the research, the average amount of pulp harvested by the three major single stations has increased by 30% this year, the utilization rate of capacity has improved significantly, and the technical exchange within the group has been more fully after the reorganization, and the yield of the three blood products has also been significantly improved. On the other hand, the sales-side company to the original sales team as the main body of the three major and Guizhou blood system integration, while giving appropriate incentive policies, unified management to bring sales efficiency improvement is obvious. (Securities Daily)